Borderless Access Launches #HealthSight# - A Programmatic Sampling Suite for Healthcare Research

Food and Healthcare Press Releases Thursday September 7, 2017 13:32
BANGALORE, CALIFORNIA and LONDON--7 Sep--PRNewswire/InfoQuest

Borderless Access, a global digital MR solutions company enters into healthcare research with the launch of its new product offering 'HealthSight', in line with its vision to be the global leader in providing digital market research solutions for collating and analysing life moments, and experiences of hard-to-reach audiences, in growing and developed markets of the world; driven by advanced analytics and technology.

(Logo: http://photos.prnewswire.com/prnh/20161017/429158LOGO )

The HealthSight platform driven by an advanced analytics engine 'SmartSight', is an end-to-end solution for healthcare research, enabling access to 150,000+ proprietary specialist physicians panel as well as provide global customers to check and test the feasibility of market research sampling designs, thereby allowing the customers to optimize their sampling and reducing project costs.

Hosted on HealthSight, the new proprietary physician panels are for developed healthcare markets such as US, UK, Canada along with growing healthcare hubs in countries like India. The HCP panels focus on general and lifestyle disease practice, orphan disease practice, and healthcare ancillary services.

Ruchika Gupta, CEO of Borderless Access says, "We are widening our network and service offering, with a unique combination of a proprietary physician panel platform due to the growing demand from clients looking for simpler research and panel design services in the healthcare space. Our HealthSight product would make clients and other Honomichl research companies more confident in the representative outcomes further increasing the market research scope and size and decreasing costs in healthcare research."

With close to 3.1 million existing panelists, this new proprietary physician panel of 150,000+ doctors and specialist physicians provides extensive targeting abilities and accuracy. To provide the additional insights towards the trends and perceptions, panel members are deeply profiled including the attributes on the segregated scenario of global markets.

Borderless Access, a global digital MR solutions company, provides access to experiences and life moments of engaged consumers from hard-to-reach audiences (consumers, B2B & specialist audiences, including healthcare) in the emerging and developed markets, driven by Technology & Community Analytics to its global clientele of MR firms, Ad agencies, consultancy firms, and end enterprises.

Its focus on innovation extends to providing market research products and solutions, such as Panel Solutions, SmartSight, HealthSight, and TAPP.
For more information, please visit: https://www.borderlessaccess.com/
Media Contact:
Anshul Agarwal
Marketing@borderlessaccess.com
Source: Borderless Access Panels Pvt Ltd.

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics